Granted Patent
B2
US 12,600,757 · App. 16/603,040 · Granted Apr 14, 2026
Peptides inhibiting gamma-c-cytokine activity and methods of use
Inventors:
Nicholas Doerr (Irvine, CA); Laith Q. Al-Mawsawi (Sherman Oaks, CA); Nazli Azimi (San Juan Capistrano, CA)
Assignee:
Bioniz Therapeutics, Inc.
C07K14/55A61K8/64A61K47/646A61K47/65A61P1/00A61P3/10A61P17/06A61P17/14A61P19/00A61P19/02A61P25/28A61P35/02A61Q3/00A61Q19/08C07K14/5443A61K38/00C07K2319/02C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed herein are stable peptide antagonists based on the consensus yc-subunit binding site to inhibit the activity of yc-cytokines. Such peptide antagonists are capable of inhibiting the activity of multiple yc-cytokine family members. The yc-family cytokines are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of yc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools.
Claims (20)
1 . A composite peptide comprising the amino acid sequence of SEQ ID NO: 83, wherein the composite peptide comprises at least one hydrocarbon linker element, and inhibits signaling activity of one or more γc-cytokines selected from the group consisting of IL-15 and IL-21.
2 . The composite peptide of claim 1 , wherein the composite peptide has enhanced gastric stability as compared to the corresponding composite peptide without a hydrocarbon linker element.
3 . The composite peptide of claim 1 , wherein the hydrocarbon linker element is an intra-peptide linker element.
4 . The composite peptide of claim 1 , wherein the at least one hydrocarbon linker element is covalently attached to one or more chemical groups or molecules selected from the group consisting of alkyl, alkaryl, aryl, aralkyl, alkoxy, thioalkoxy, aryloxy, haloalkyl, halo, oxo, nitro, hydroxy, mercapto, carboxy, alkylcarbonyl, alkoxycarbonyl, alkanesulfonyl, amino, amido, azido, cyano, PEG, affinity labels, targeting moiety, fatty-acid derived acyl group, biotin, radioisotopes, non-protein fluorescent chemical groups, and protein fluorescent molecules.
5 . A pharmaceutical composition comprising:
the composite peptide of claim 1 ; and
a pharmaceutically acceptable carrier, diluent, excipient or combination thereof.
6 . A kit comprising the pharmaceutical composition of claim 5 .
7 . A method of treating an IL-15 or IL-21-mediated disease, the method comprising administering the pharmaceutical composition of claim 5 .
8 . The method of claim 7 , wherein the IL-15 or IL-21-mediated disease is celiac disease or refractory celiac disease.
9 . A composite peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 12 and 24, wherein the composite peptide comprises at least one hydrocarbon linker element, and inhibits signaling activity of one or more γc-cytokines selected from the group consisting of IL-15 and IL-21.
10 . The composite peptide of claim 9 , wherein the composite peptide has enhanced gastric stability as compared to the corresponding composite peptide without a hydrocarbon linker element.
11 . The composite peptide of claim 9 , wherein the hydrocarbon linker element is an intra-peptide linker element.
12 . The composite peptide of claim 9 , wherein the at least one hydrocarbon linker element is covalently attached to one or more chemical groups or molecules selected from the group consisting of alkyl, alkaryl, aryl, aralkyl, alkoxy, thioalkoxy, aryloxy, haloalkyl, halo, oxo, nitro, hydroxy, mercapto, carboxy, alkylcarbonyl, alkoxycarbonyl, alkanesulfonyl, amino, amido, azido, cyano, PEG, affinity labels, targeting moiety, fatty-acid derived acyl group, biotin, radioisotopes, non-protein fluorescent chemical groups, and protein fluorescent molecules.
13 . A pharmaceutical composition comprising:
the composite peptide of claim 9 ; and
a pharmaceutically acceptable carrier, diluent, excipient or combination thereof.
14 . A kit comprising the pharmaceutical composition of claim 13 .
15 . A method of treating an IL-15 or IL-21-mediated disease, the method comprising administering the pharmaceutical composition of claim 13 .
16 . The method of claim 15 , wherein the IL-15 or IL-21-mediated disease is celiac disease or refractory celiac disease.
Assignments (2)
MERGER AND CHANGE OF NAME
Recorded Oct 6, 2023
From: BIONIZ, LLC; BIONIZ THERAPEUTICS, INC.
To: BIONIZ THERAPEUTICS, INC.
Reel/Frame 065153/0383 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 4, 2019
From: DOERR, NICHOLAS; AL-MAWSAWI, LAITH Q.; AZIMI, NAZLI
To: BIONIZ, LLC
Reel/Frame 050631/0830 →
Continuity (2)
Provisional Application
62483210
· Apr 7, 2017
References Cited (400)
US 4518584A
· Mark et al.
· 1985
[cited by applicant]
US 5700913A
· Taniguchi et al.
· 1997
[cited by applicant]
US 5795966A
· Grabstein et al.
· 1998
[cited by applicant]
US 6013480A
· Grabstein et al.
· 2000
[cited by applicant]
US 6028186A
· Tasset et al.
· 2000
[cited by applicant]
US 6127387A
· Huang et al.
· 2000
[cited by applicant]
US 6168783B1
· Grabstein et al.
· 2001
[cited by applicant]
US 6261559B1
· Levitt et al.
· 2001
[cited by applicant]
US 6307024B1
· Novak et al.
· 2001
[cited by applicant]
US 6323027B1
· Burkly et al.
· 2001
[cited by applicant]
US 6686178B2
· Novak et al.
· 2004
[cited by applicant]
US 6770745B2
· Burkly et al.
· 2004
[cited by applicant]
US 6793919B2
· Mohler
· 2004
[cited by applicant]
US 6797263B2
· Strom et al.
· 2004
[cited by applicant]
US 6811780B2
· Furfine et al.
· 2004
[cited by applicant]
US 6838433B2
· Serlupi-Crescenzi
· 2005
[cited by applicant]
US 6955807B1
· Shanafelt et al.
· 2005
[cited by applicant]
US 7105653B2
· Shanafelt et al.
· 2006
[cited by applicant]
US 7148333B2
· Cox, III
· 2006
[cited by applicant]
US 7192578B2
· Levitt et al.
· 2007
[cited by applicant]
US 7235240B2
· Grabstein et al.
· 2007
[cited by applicant]
US 7314623B2
· Grusby et al.
· 2008
[cited by applicant]
US 7347995B2
· Strom et al.
· 2008
[cited by applicant]
US 7423123B2
· Boisvert et al.
· 2008
[cited by applicant]
US 7473765B2
· Novak et al.
· 2009
[cited by applicant]
US 7632814B2
· Hazlehurst et al.
· 2009
[cited by applicant]
US 7645449B2
· Stassi et al.
· 2010
[cited by applicant]
US 7700088B2
· Levitt et al.
· 2010
[cited by applicant]
US 7731946B2
· Grusby et al.
· 2010
[cited by applicant]
US 7785580B2
· Pan et al.
· 2010
[cited by applicant]
US 7786072B2
· Verdine et al.
· 2010
[cited by applicant]
US 7910123B2
· McKay
· 2011
[cited by applicant]
US 7959908B2
· Nelson et al.
· 2011
[cited by applicant]
US 8110180B2
· Novak et al.
· 2012
[cited by applicant]
US 8211420B2
· Bondensgaard
· 2012
[cited by applicant]
US 8455449B2
· Tagaya
· 2013
[cited by applicant]
US 8512946B2
· Mirkin et al.
· 2013
[cited by applicant]
US 9133243B2
· Tagaya
· 2015
[cited by applicant]
US 9133244B2
· Tagaya
· 2015
[cited by applicant]
US 9675672B2
· Tagaya
· 2017
[cited by applicant]
US 9951105B2
· Tagaya
· 2018
[cited by applicant]
US 9959384B2
· Azimi et al.
· 2018
[cited by applicant]
US 20020114781A1
· Strom et al.
· 2002
[cited by applicant]
US 20040009150A1
· Nelson et al.
· 2004
[cited by applicant]
US 20050124044A1
· Cunningham et al.
· 2005
[cited by applicant]
US 20060034892A1
· Ueno
· 2006
[cited by applicant]
US 20060039902A1
· Young et al.
· 2006
[cited by applicant]
US 20060236411A1
· Dreher et al.
· 2006
[cited by applicant]
US 20070048266A1
· Nelson
· 2007
[cited by applicant]
US 20070048831A1
· Sprecher et al.
· 2007
[cited by applicant]
US 20070122413A1
· Sivakumar et al.
· 2007
[cited by applicant]
US 20080166338A1
· Leonard
· 2008
[cited by applicant]
US 20090148403A1
· Bosivert et al.
· 2009
[cited by applicant]
US 20100099742A1
· Stassi
· 2010
[cited by applicant]
US 20100135958A1
· Hwu
· 2010
[cited by applicant]
US 20110091515A1
· Zilberman et al.
· 2011
[cited by applicant]
US 20110142833A1
· Young
· 2011
[cited by applicant]
US 20110245090A1
· Abbas
· 2011
[cited by applicant]
US 20110311475A1
· Borte
· 2011
[cited by applicant]
US 20230060637A1
· Azimi
· 2023
[cited by applicant]
US 20230197187A1
· Azimi et al.
· 2023
[cited by applicant]
US 20230338473A1
· Tagaya et al.
· 2023
[cited by applicant]
US 20240043475A1
· Tagaya et al.
· 2024
[cited by applicant]
US 20240209025A1
· Tagaya et al.
· 2024
[cited by applicant]
US 20240317848A1
· Tagaya et al.
· 2024
[cited by applicant]
CN 1478098
· 2004
[cited by applicant]
CN 1703423
· 2005
[cited by applicant]
CN 103501805A
· 2014
[cited by applicant]
CN 103501805B
· 2018
[cited by applicant]
EP 1525213
· 2005
[cited by applicant]
EP 2665486A1
· 2013
[cited by applicant]
JP 2004525076
· 2004
[cited by applicant]
JP 2005508179
· 2005
[cited by applicant]
WO WO8702990A1
· 1987
[cited by applicant]
WO WO200072864A1
· 2000
[cited by applicant]
WO WO2003040313A1
· 2003
[cited by applicant]
WO WO03087320
· 2003
[cited by applicant]
WO WO2003103589A2
· 2003
[cited by applicant]
WO WO2004084835A2
· 2004
[cited by applicant]
WO WO2005014642A2
· 2005
[cited by applicant]
WO WO2005030196A2
· 2005
[cited by applicant]
WO WO2005067956A2
· 2005
[cited by applicant]
WO WO2005105830A1
· 2005
[cited by applicant]
WO WO2005112983A2
· 2005
[cited by applicant]
WO WO2006105538A2
· 2006
[cited by applicant]
WO WO2006111524A2
· 2006
[cited by applicant]
WO WO2006113331A1
· 2006
[cited by applicant]
WO WO2008049920A2
· 2008
[cited by applicant]
WO WO2009100035A2
· 2009
[cited by applicant]
WO WO2009108341A1
· 2009
[cited by applicant]
WO WO2009132821A1
· 2009
[cited by applicant]
WO WO2010011313A2
· 2010
[cited by applicant]
WO WO2010039533A2
· 2010
[cited by applicant]
WO WO2010054667A1
· 2010
[cited by applicant]
WO WO2010076339A1
· 2010
[cited by applicant]
WO WO2010103038A1
· 2010
[cited by applicant]
WO WO2010133828A1
· 2010
[cited by applicant]
WO WO2011008260A1
· 2011
[cited by applicant]
WO WO2011070214A2
· 2011
[cited by applicant]
WO WO2011133948A2
· 2011
[cited by applicant]
WO WO2012006585A2
· 2012
[cited by applicant]
WO WO2012012531A2
· 2012
[cited by applicant]
WO WO2012099886
· 2012
[cited by applicant]
WO WO2012175222A1
· 2012
[cited by applicant]
WO WO2015089217A2
· 2015
[cited by applicant]
WO WO2015089217A3
· 2015
[cited by applicant]
WO WO2017062685A1
· 2017
[cited by applicant]
WO WO2018187499A1
· 2018
[cited by applicant]
Antony, et al., “Interleukin-2-Dependent Mechanisms of Tolerance and Immunity In Vivo,” J. Immunol. 176: 5255-5266, 2006.
[cited by applicant]
Azimi, N., “Human T Cell Lymphotropic Virus Type I Tax Protein Trans-Activates Interleukin 15 Gene Transcription Through an NF-kappaB Site,” Proc. Natl. Acad. Sci. USA 95:2452-2457, 1998.
[cited by applicant]
Azimi, N., “Involvement of IL-15 In The Pathogenesis of Human T Lymphotropic Virus Type-I-Associated Myelopathy/Tropical Spastic Paraparesis: Implications for Therapy with a Monoclonal Antibody Directed to the IL-2/15Rb…
[cited by applicant]
Azimi, N., et al., “How Does Interleukin 15 Contribute to the Pathogenesis of HTLV Type-1 Associated Myelopathy/Tropical Spastic Paraparesis?” AIDS Res. Hum. Retroviruses 16:1717-1722, 2000.
[cited by applicant]
Azimi, N., et al., “IL-15 Plays a Major Role in the Persistence of Tax-specific CD8 Cells in HAM/TSP patients,” Proc. Natl. Acad. Sci. 98:14559-14564, 2001.
[cited by applicant]
Bazan, J.F., “Hematopoietic Receptors and Helical cytokines,” Immunol. Today 11:350-354, 1990.
[cited by applicant]
Bernard et al., dentification of an Interleukin-15α Receptor-binding Site on Human Interleukin-15*, The Journal of Biological Chemistry (2004)279:24313-24322.
[cited by applicant]
Bettini, M., and D.A. Vignali, “Regulatory T Cells and Inhibitory Cytokines in Autoimmunity,” Curr. Opin. Immunol. 21:612-618, 2009.
[cited by applicant]
Bodd, M., et al., “HLA-DQ2-Restricted Gluten-Reactive T cells Produce IL-21 but not IL-17 or IL-22,” Mucosal Immunol. 3:594-601, 2010.
[cited by applicant]
Bonsch, et al Species-specific Agonist/Antagonist Activities of Human Interleukin-4 Variants Suggest Distinct Ligand Binding Properties of Human and Murine Common Receptor γChain, The Journal of Biological Chemistry (19…
[cited by applicant]
De Rezende, L.C., et al., “Regulatory T Cells as a Target for Cancer Therapy,” Arch. Immunol. Ther. Exp. 58:179-190, 2010.
[cited by applicant]
Decision of Rexamination Received Jun. 27, 2017 in Chinese Application 201280010348.8.
[cited by applicant]
Definition of composite from www.merriam-sebster.com/dictionary/composite, pp. 1-5. Accessed Feb. 17, 2015.
[cited by applicant]
Definition of derivative from http://cancerweb.ncl.ac.uk/omd/about.html, pp. 1-5. Accessed Jul. 7, 2005.
[cited by applicant]
Dubois, S., et al., “IL-15R alpha Recycles and Presents IL-15 In Trans to Neighboring Cells,” Immunity 17:537-547, 2002.
[cited by applicant]
Examination Report Dated Nov. 14, 2018 in Australian Patent Application No. 2016334085.
[cited by applicant]
Extended EP Search report dated May 22, 2014 for PCT/US2012/021566.
[cited by applicant]
Extended European Search Report Dated Mar. 28, 2019 in European Patent Application No. 16854367.6.
[cited by applicant]
Fehniger, T.A., “Fatal Leukemia in Interleukin 15 Transgenic Mice Follows Early Expansions in Natural Killer and Memory Phenotype CD8+ T Cells,” J. Exp. Med. 193:219-231, 2001.
[cited by applicant]
Final Office Action dated Feb. 24, 2015 for U.S. Appl. No. 13/868,725.
[cited by applicant]
Final Office Action dispatched Nov. 29, 2016 for JP Patent Application 2013-550541.
[cited by applicant]
Final Office Action dated Dec. 13, 2017 for U.S. Appl. No. 15/585,666.
[cited by applicant]
Fisher, A.G. et al., “Lymphoproliferative disorders in an IL-7 transgenic mouse line,” Leukemia 2, 1993, pp. 66-68.
[cited by applicant]
Gong, J.H. et al., Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8, 1994, pp. 652-658.
[cited by applicant]
Hennighausen, L., and G.W. Robinson, “Interpretation of Cytokine Signaling Through the Transcription Factors STAT5A and STAT5B,” Genes Dev. 22:711-721, 2008.
[cited by applicant]
Hines, L et at. Interleukin 15, partial [synthetic construct]. NCBI PDS Accession No. AAX36174, interleukin 15, partial [synthetic construct]. Submitted Jan. 5, 2005; downloaded from the internet <https://www.ncbi.nlm.n…
[cited by applicant]
Hodge, D.L., et al., IL-2 and IL-12 Alter NK Cell Responsiveness to IFN-Gamma-Inducible Protein 10 by Down-Regulating CXCR3 Expression, J. Immun. 168:6090-6098, 2002.
[cited by applicant]
International Preliminary Report on Patentability dated Jul. 23, 2013 for PCT/US2012/021566.
[cited by applicant]
International Preliminary Report on Patentability issued Jun. 14, 2016 for PCT/US2012/062870.
[cited by applicant]
International Preliminary Report on Patentability issued Apr. 10, 2018 for PCT/US2016/055845.
[cited by applicant]
International Search Report and Written Opinion dated Jan. 17, 2017 for PCT/US2016/055845.
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority in International Application No. PCT/US2012/021566 mailed May 10, 2012.
[cited by applicant]
International Search Report dated Jun. 26, 2015 for PCT/US14/69597.
[cited by applicant]
International Search Report and Written Opinion dated Aug. 23, 2018 for PCT/US2018/026125.
[cited by applicant]
Klingemann, H.G. et al., “A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood,” Blood Marrow Transplant 2, 1996, pp. 68-75.
[cited by applicant]
Krause, C.D. and S. Pestka, “Evolution of the Class 2 Cytokines and Receptors, and Discovery of New Friends and Relatives,” Pharmacol. and Therapeutics 106:299-346, 2005.
[cited by applicant]
Kundig, T.M. et al. “Immune Responses of the interleukin-2-deficient mice,” Science 262, 1993, pp. 1059-1061.
[cited by applicant]
Le Buanec, H., et al., “Control of Allergic Reactions in Mice by an Active Anti-Murine IL-4 Immunization,” Vaccine 25:7206-7216, 2007.
[cited by applicant]
Littman, D.R., and A. Y. Rudensky, “Th17 and Regulatory T Cells in Mediating and Restraining Inflammation,” Cell 140(6):845-858, 2010.
[cited by applicant]
Miyagawa, F., et al., “IL-15 Serves as a Costimulator in Determining the Activity of Autoreactive CD8 T Cells in an Experimental Mouse Model of Graft-Versus-Host-Like Disease,” J. Immunol. 181:1109-1119, 2008.
[cited by applicant]
NCBI Accession No. ABF82250, Accessed Aug. 11, 2014.
[cited by applicant]
NCBI Accession No. BAA96385, Accessed Aug. 11, 2014.
[cited by applicant]
NCBI Accession No. NP_999580, Accessed Aug. 11, 2014.
[cited by applicant]
NCBI Accession No. ACT78884, Accessed Aug. 11, 2014.
[cited by applicant]
NCBI Accession No. NP_999288, Accessed Aug. 11, 2014.
[cited by applicant]
Noguchi, M., et al., “Interleukin 2 Receptor Gamma Chain Mutation Results in X-linked Severe Combined Immunodeficiency in Humans,” Cell 73:147-157, 1993.
[cited by applicant]
Notice of Acceptance dated Oct. 19, 2016 for AU Application 2012207456.
[cited by applicant]
Notice of Allowance dated Feb. 19, 2013 for U.S. Appl. No. 13/589,017.
[cited by applicant]
Notice of Allowance dated Feb. 6, 2017 for U.S. Appl. No. 14/852,240.
[cited by applicant]
Notice of Allowance dated May 11, 2015 for U.S. Appl. No. 13/868,725.
[cited by applicant]
Notice of Allowance dated May 4, 2015 for U.S. Appl. No. 13/980,305.
[cited by applicant]
Notice of Allowance dated Dec. 15, 2017 in U.S. Appl. No. 15/179,900.
[cited by applicant]
Notice of Allowance dated Dec. 19, 2017 for U.S. Appl. No. 15/103,804.
[cited by applicant]
Notification of Allowance Dated May 31, 2018 for CN Patent Application 201280010348.8.
[cited by applicant]
Notice of Allowance Dated Mar. 26, 2018 in U.S. Appl. No. 15/287,517.
[cited by applicant]
Notice of Allowance Dated Mar. 26, 2018 in U.S. Appl. No. 15/585,666.
[cited by applicant]
Notice of Allowance dated Aug. 15, 2018 for JP Patent Application 2013-550541.
[cited by applicant]
Notice of Allowance dated Oct. 22, 2018 for U.S. Appl. No. 15/474,312.
[cited by applicant]
Notice of Allowance dated Jul. 5, 2019 for EP Patent Application No. 12736203.6.
[cited by applicant]
Notification of Re-examination issued Mar. 24, 2017 for CN Patent Application 201280010348.8.
[cited by applicant]
O'Shea, J.J., “Targeting the Jak/STAT Pathway for Immunosuppression,” Ann. Rheum. Dis. 63:(Suppl. II):ii67-71, 2004.
[cited by applicant]
Olosz, F. et al. Structural Baisis for Binding Multiple Ligands by the Common Cytokine Receptor [gamma]-chain, Journal of Biological Chemistry, vol. 277, No. 14, pp. 12047-12052, (2002).
[cited by applicant]
Office Action dated Aug. 18, 2014 for U.S. Appl. No. 13/868,725.
[cited by applicant]
Office Action dated Aug. 3, 2017for U.S. Appl. No. 15/103,804.
[cited by applicant]
Office Action dated Aug. 8, 2017for U.S. Appl. No. 15/585,666.
[cited by applicant]
Office Action dated Jan. 26, 2016 for JP Patent Application 2013-550541.
[cited by applicant]
Office Action dated Jul. 2, 2014 for corresponding CN Application 201280010348.8.
[cited by applicant]
Office Action dated Jul. 24, 2017 in U.S. Appl. No. 15/179,900.
[cited by applicant]
Office Action dated Jul. 4, 2016 for Chinese Patent Application No. 201280010348.8.
[cited by applicant]
Office Action dated Nov. 12, 2014 for U.S. Appl. No. 13/980,305.
[cited by applicant]
Office Action dated Oct. 26, 2016 in EP Patent Application No. 12736203.6.
[cited by applicant]
Office Action dated Oct. 18, 2014 for U.S. Appl. No. 13/868,725.
[cited by applicant]
Office Action dated Oct. 22, 2015 for AU Application 2012207456.
[cited by applicant]
Office Action dated Oct. 27, 2015 for Chinese Patent Application No. 201280010348.8.
[cited by applicant]
Office Action dated Sep. 6, 2016 for U.S. Appl. No. 14/852,240.
[cited by applicant]
Office Action issued Apr. 28, 2015 for Chinese Patent Application No. 201280010348.8.
[cited by applicant]
Office Action Dated Oct. 4, 2017 in European Patent Application No. 12736203.6.
[cited by applicant]
Office Action Dated Oct. 23, 2017 in U.S. Appl. No. 15/287,517.
[cited by applicant]
Office Action Dated Nov. 22, 2017 in Canadian Application No. 2,824,51.
[cited by applicant]
Office Action Dated Feb. 9, 2018 in Australian Application No. 2017200489.
[cited by applicant]
Office Action dated Feb. 20, 2018 for JP Patent Application 2013-550541.
[cited by applicant]
Office Action dated May 8, 2018 in JP Patent Application No. 2017-90501.
[cited by applicant]
Office Action dated Jun. 22, 2018 for U.S. Appl. No. 15/474,312.
[cited by applicant]
Office Action Dated Nov. 14, 2018 in Australian Patent Application No. 2016334085.
[cited by applicant]
Office Action Dated Nov. 23, 2018 in Canadian Application No. 2,824,51.
[cited by applicant]
Office Action Dated Nov. 26, 2018 in European Patent Application No. 12736203.6.
[cited by applicant]
Office Action Dated Jan. 31, 2019 in Canadian Patent Application No. 3,000,207.
[cited by applicant]
Office Action dated Apr. 23, 2019 in JP Patent Application No. 2017-90501.
[cited by applicant]
Office Action Dated Jun. 4, 2019 in JP Patent Application No. 2018-517887.
[cited by applicant]
Office Action dated Aug. 16, 2019 for U.S. Appl. No. 15/957,806.
[cited by applicant]
Office Action dated Sep. 9, 2019 for U.S. Appl. No. 15/964,717.
[cited by applicant]
Office Action dated Sep. 25, 2019 for KR Patent Application No. 10-2018-7013183.
[cited by applicant]
Office Action dated Oct. 28, 2019 for AU Patent Application No. 2016334085.
[cited by applicant]
Oh, U., and S. Jacobson, “Treatment of HTLV-I-Associated Myelopathy / Tropical Spastic Paraparesis: Towards Rational Targeted Therapy,” Neurol. Clin. 26:781-785, 2008.
[cited by applicant]
Orzaez, M., et al., “Peptides and Peptide Mimics as Modulators of Apoptotic Pathways,” Chem. Med. Chem. 4:146-160, 2009.
[cited by applicant]
Paul, W.E., “Pleiotropy and Redundancy: T Cell-Derived Lymphokines in the Immune Response,” Cell 57:521-524, 1989.
[cited by applicant]
Pesu, M., “Jak3, Severe Combined Immunodeficiency, and a New Class of Immunosuppressive Drugs,” Immunol. Rev. 203:127-142, 2005.
[cited by applicant]
Pesu, M., Laurence, et al., “Therapeutic Targeting of Janus Kinases,” Immunol. Rev. 223:132-142, 2008.
[cited by applicant]
Restriction Requirement dated Feb. 28, 2017 for U.S. Appl. No. 15/179,900.
[cited by applicant]
Restriction Requirement dated Jul. 25, 2017 in U.S. Appl. No. 15/287,517.
[cited by applicant]
Restriction Requirement dated Jun. 24, 2014 for U.S. Appl. No. 13/980,305.
[cited by applicant]
Restriction Requirement dated Mar. 24, 2017 for U.S. Appl. No. 15/103,804.
[cited by applicant]
Restriction Requirement dated May 9, 2014 for U.S. Appl. No. 13/868,725.
[cited by applicant]
Restriction Requirement dated Jan. 26, 2018 for U.S. Appl. No. 15/474,312.
[cited by applicant]
Restriction Requirement dated Mar. 22, 2019 for U.S. Appl. No. 15/957,806.
[cited by applicant]
Restriction Requirement dated Apr. 8, 2019 for U.S. Appl. No. 15/964,717.
[cited by applicant]
Rochman, Y., et al., “New Insights into the Regulation of T Cells by Gamma C Family Cytokines,” Nat. Rev. Immunol. 9:480-490, 2009.
[cited by applicant]
Sakaguchi, S., et al., “Regulatory T Cells and Immune Tolerance,” Cell 133:775-787, 2008.
[cited by applicant]
Sato, N., et al., “Development of an IL-15-Autocrine CD8 T-cell Leukemia in IL-15 Transgenic mice requires the cis-expression of IL-15R apha,” Blood 2011.
[cited by applicant]
Sugamura, K., et al., “The Common Gamma-Chain for Multiple Cytokine Receptors,” Adv. Immunol. 59:225-277, 1995.
[cited by applicant]
Sugamura, K., et al., “The Interleukin-2 Receptor Gamma Chain: Its Role in the Multiple Cytokine Receptor Complexes and T Cell Development in XSCID,” Annu. Rev. Immunol. 14:179-205, 1996.
[cited by applicant]
Supplementary European Search Report dated May 22, 2014 for European Application No. 12784848.9.
[cited by applicant]
Tagaya, Y., “Memory CD8 T Cells Now Join 'Club 21,” J. Leuk. Biol. 87:13-15, 2010.
[cited by applicant]
Tagaya, Y., et al., “Identification of a Novel Receptor/Signal Transduction Pathway for IL-15/T in Mast Cells,” EMBO J. 15:4928-4939, 1996.
[cited by applicant]
Takai, K. et al., The Wheat-Germ Cell-Free Expression System, Curr. Pharm. Biotechnol. 11, 2010, pp. 272-278.
[cited by applicant]
Takeshita, T., et al., “Cloning of the Gamma Chain of the Human IL-2 Receptor,” Science 257:379-382, 1992.
[cited by applicant]
Tanaka, T., et al., “A Novel Monoclonal Antibody Against Murine IL-2 Receptor Beta-Chain. Characterization of Receptor Expression in Normal Lymphoid Cells and EL-4 Cells,” J. Immunol. 147:2222-2228, 1991.
[cited by applicant]
Waldmann, T.A., Anti-Tac (daclizumab, Zenapax) in the Treatment of Leukemia, Autoimmune Diseases, and in the Prevention of Allograft Rejection: A 25-Year Personal Odyssey, J. Clin. Immunol. 27:1-18, 2007.
[cited by applicant]
Water is naturally occurring from www.biology-online.org/dictionary/Water, pp. 1-3, Accesssed Apr. 24, 2014.
[cited by applicant]
Yampolsky, L. et al., The Exchangeability of Amino Acids in Proteins, Genetics, 170, pp. 1459-1472, (2005).
[cited by applicant]
Notice of Acceptance Dated Jan. 14, 2019 in Australian Application No. 2017200489.
[cited by applicant]
Notice of Allowance Dated Feb. 26, 2020 in U.S. Appl. No. 15/957,806.
[cited by applicant]
Final Office Action dated Feb. 26, 2020 for U.S. Appl. No. 15/964,717.
[cited by applicant]
Office Action dated Feb. 26, 2021 for Chinese Patent Application No. 201810863447.X.
[cited by applicant]
Office Action dated Feb. 11, 2021 in U.S. Appl. No. 15/767,133.
[cited by applicant]
Abadie et al., “IL-15: A central regulator of celiac disease immunopathology”. Immunol Rev. (2014) 260(1): 221-234.
[cited by applicant]
Aringer et al., “Serum interleukin-15 is elevated in systemic lupus erythematosus”, Rheumatology (2001) 40(8):876-881.
[cited by applicant]
Asano et al., “Molecular scanning of interleukin-21 gene and genetic susceptibility to type 1 diabetes.” Hum Immunol. (2007) 68(5):384-391.
[cited by applicant]
Atwa et al., “T-helper 17 cytokines (interleukins 17, 21, 22, and 6, and tumor necrosis factor-α) in patients with alopecia areata: association with clinical type and severity”. Int J Dermatol. (2016) 55(6):666-672.
[cited by applicant]
Awwad et al., “Overview of Antibody Drug Delivery”. Pharmaceutics (2018) 10(3): 83.
[cited by applicant]
Baranda et al., “IL-15 and IL-15R in leucocytes from patients with systemic lupus erythematosus.” Rheumatology (2005) 44(12): 1507-1513.
[cited by applicant]
Ben Ahmed et al., “IL-15 renders conventional lymphocytes resistant to suppressivefunctions of regulatory T cells through activation of the phosphatidylinositol 3-kinase pathway”. J Immunol. (2009) 182(11):6763-6770.
[cited by applicant]
Benahmed et al., “Inhibition of TGF-beta signaling by IL-15: a new role for IL-15 in the loss of immune homeostasis in celiac disease”. Gastroenter. (2007) 132(3):994-1008.
[cited by applicant]
Blaser et al., “Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease”. Blood (2005) 105(2): 894-901.
[cited by applicant]
Bla{circumflex over (z)}ek et al., “The production and application of single-chain antibody fragments”. Folia Microbiol. (2003) 48(5): 687-698.
[cited by applicant]
Bobbala et al., “Interleukin-15 plays an essential role in the pathogenesis of autoimmune diabetes in the NOD mouse”, Diabetologia (2012) 55: 3010-3020.
[cited by applicant]
Borrego et al., “Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis”. J …
[cited by applicant]
Botti et al., “Psoriasis, from pathogenesis to therapeutic strategies: IL-21 as a novel potential thereapeutic target”. Curr Pharm Biotechnol. (2012) 13(10): 1861-1867.
[cited by applicant]
Broux et al., “IL-15 amplifies the pathogenic properties of CD4+CD28- T cells in multiple sclerosis”. J Immunol. (2015) 194(5): 2099-2109.
[cited by applicant]
Brumbaugh et al., “Clonotypic differences in signaling from CD94 (kp43) on NK cells lead to divergent cellular responses”. J Immunol. (1996) 157(7): 2804-2812.
[cited by applicant]
Bubier et al., “A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice.” Proc Natl Acad Sci U S A (2009) 106(5):1518-1523.
[cited by applicant]
Bucher et al., “IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation”. 2009 114:5375-84.
[cited by applicant]
Cantoni et al., “The activating form of CD94 receptor complex: CD94 covalently associates with the Kp39 protein that represents the product of the NKG2-C gene”. Eur J Immunol. (1998) 28: 327-338.
[cited by applicant]
Caruso et al., “Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis”. Nature Med. (2009) 15((): 1013-1015.
[cited by applicant]
Caruso et al., “Pathogenic role of interleukin-21 in psoriasis.” Cell Cycle (2009) 8: 3629-3630.
[cited by applicant]
Chen et al., “Insulin-dependent diabetes induced by pancreatic betacell expression of IL-15 and IL-15R alpha”, Proc Natl Acad Sci U S A (2013) 110:13534-13539.
[cited by applicant]
Chen et al., “Induction of autoimmune diabetes in non-obese diabetic mice requires|interleukin-21-dependent activation of autoreactive CD8+ T cells”. Clin Exp Immunol. (2013) 173(2): 184-194.
[cited by applicant]
Chik et al., “Elevated serum interleukin-15 level in acute graft-versus-host disease after hematopoietic cell transplantation.” J Pediatr Hematol Oncol. (2003) 25(12): 960-964.
[cited by applicant]
Cox et al., “Immunoassay methods”, in Assay Guidance Manual [Internet], S. Markossian, G.S. Sittampalam, N.P. Coussens, H. Nelson, et al. [Eds.] (Bethesda, MD: Eli Lilly & Company and the National Center for Advancing T…
[cited by applicant]
D'Auria et al., “Increased serum interleukin-15 levels in bullous skin diseases: correlation with disease intensity”. Arch Dermatol Res. (1999) 291: 354-356.
[cited by applicant]
De Nitto et al., “Involvement of interleukin-15 and interleukin-21, two gamma-chain-related cytokines, in deiac disease”, World J Gastroenter. (2009) 15:4609-4614.
[cited by applicant]
De Nitto et al. “Interleukin-21 triggers effector cell responses in the gut.” World J Gastroenterol. (2010) 16(29):3638-3641.
[cited by applicant]
DePaolo et al., “Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens”. Nature (2011) 471(7337): 220-224.
[cited by applicant]
Di Sabatino A. et al., “Epithelium derived interleukin 15 regulates intraepithelial lymphocyte Th1 cytokine production, cytotoxicity, and survival in coeliac disease”, Gut (2006) 55(4):469-477.
[cited by applicant]
Fang et al., “Prophylactic effects of interleukin-2 receptor antagonists against graft-versus-host disease following unrelated donor peripheral blood stem cell transplantation”. Biol Blood Marrow Transplant. (2012) 18(5…
[cited by applicant]
Ferreira et al., “IL-21 production by CD4+ effector T cells and frequency of circulating follicular helper T cells are increased in type 1 diabetes patients”, Diabetologia (2015) 58: 781-790.
[cited by applicant]
Fina et al., “Interleukin 21 contributes to the mucosal T helper cell type 1 resonse in coeliac disease”. Gut (2008) 57(7):887-892.
[cited by applicant]
Frenzel et al., “Designing Human Antibodies by Phage Display”. Transfus Med Hemother. (2017) 44(5): 312-318.
[cited by applicant]
Fuentes-Duculan et al., “Biomarkers of alopecia areata disease activity and response to corticosteroid treatment”. Exp Dermatol. (2016) 4:282-286.
[cited by applicant]
Garrity et al., “The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure”. Proc Natl Acad Sci. (2005) 102(21): 7641-7646.
[cited by applicant]
Ghalamfarsa et al., “IL-21 and IL-21 receptor in theimmunopathogenesis of multiple sclerosiS”, J Immunotoxicol. (2016) 13(3):274-285.
[cited by applicant]
Gilhar et al., “Alopecia areata animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies”. Autoimmun Rev. (2016) 15(7): 726-735.
[cited by applicant]
Gonzalez-Alvaro et al., “Increased serum levels of interleukin-15 in rheumatoid arthritis with long-term disease.” Clin Exp Rheumatol. (2003) 21(5):639-642.
[cited by applicant]
Grando et al., “Mediators of inflammation in blister fluids from patients with pemphigus vulgaris and bullous pemphigoid”. 1989 Arch Dermatol. (1989) 125:925-930.
[cited by applicant]
Groh et al., “Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis”. Proc Natl Acad Sci U S A. (2003) 100(16):9452-9457.
[cited by applicant]
Guo-Qiang et al., “Guided selection methods through chain shuffling”. Methods Mol Biol. (2009) 562(10): 133-142.
[cited by applicant]
Habib T. et al., “IL-21: a novel IL-2-family lymphokine that modulates B,T, and natural killer cell responses”, J Allergy Clin Immunol. (2003) 112(6):1033-1045.
[cited by applicant]
Hammers et al., “Antibody Phage Display: Technique and Applications”. J Invest Dermatol. (2014) 134(2): e17; 13 pages.
[cited by applicant]
Harada et al., “Production of interleukin-7 and interleukin-15 by fibroblast-like synoviocytes from patients with rheumatoid arthritis.” Arthritis Rheum. (1999) 42(7):1508-1516.
[cited by applicant]
He et al., “Elevated serum levels of interleukin 21 are associated with disease severity in patients with psoriasis.” Br J Dermatol. (2012) 167: 191-193.
[cited by applicant]
Hessian P.A. et al., “Cytokine profile of the rheumatoid nodule suggests that it is a Th1 granuloma.” Arthritis Rheum. (2003) 48(2):334-338.
[cited by applicant]
Hippen et al., “Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes”. Blood (2012) 119(2): 619-628.
[cited by applicant]
Hodge et al., “IL-2 and IL-12 alter NK cell responsiveness to IFN-gamma-inducible protein 10 by down-regulating CXCR3 expression”. J Immunol. (2002) 168(12): 6090-6098.
[cited by applicant]
Hong et al., Regulatory and pro-inflammatory phenotypes of myelin basic protein-autoreactive T cells in multiple sclerosis. Int Immunol. (2009) 21(12): 1329-1340.
[cited by applicant]
Hüe et al., “A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease.” Immunity (2004) 21(3): 367-377.
[cited by applicant]
Jabri B. et al., “Selective expansion of intraepithelial lymphocytes expressing the HLA-E-specific natural killer receptor CD94 in celiac disease”, Gastroenter. (2000) 118:867-879.
[cited by applicant]
Jagielska et al., “Follow-up study of the first genome-wide association scan in alopecia areata: IL13 and KIAA0350 as susceptibility loci supported with genome-wide significance.” J Invest Dermatol. (2012) 132:2192-2197.
[cited by applicant]
Jespers et al., “Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen”. Biotechnology (1994) 12: 899-903.
[cited by applicant]
Jespersen et al., “BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes”. Nucleic Acids Res. (2017) 45(W1): W24-W29.
[cited by applicant]
Kang et al., Rational Design of Interleukin-21 Antagonist through Selective Elimination of the C Binding Epitope, J Biol Chem. (2010) 285(16): 12223-12231.
[cited by applicant]
Kivisäkk et al., “IL-15 mRNA expression is up-regulated in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis (MS)”, Clin Exp Immunol. (1998) 111(1):193-197.
[cited by applicant]
Kluczyk et al., “The “two-headed” peptide inhibitors of interleukin-1 action,” Peptides, (200), 21: 1411-1420.
[cited by applicant]
Köhler et al., “Continuous cultures of fused cells secreting antibody of predefined specificity”. Nature (1975) 256(5517): 495-497.
[cited by applicant]
Kooy-Winkelaar et al., “CD4 T-cell cytokines synergize to induce proliferation of malignant and nonmalignant innate intraepithelial lymphocytes”, Proc Natl Acad Sci U S A (2017)114(6): E980-989.
[cited by applicant]
Kuczynski et al., “IL-15 is elevated in serum patients with type 1 diabetes mellitus.” Diabetes Res Clin Pract. (2005) 69(3):231-236.
[cited by applicant]
Laffleur et al., “Production of human or humanized antibodies in mice”. In Antibody Methods and Protocols by G. Proetzel et al.,[Ed.]. (2012) 901:149-159 (TOC only).
[cited by applicant]
Lazetic et al., “Human natural killer cell receptors involved in MHC class I recognition are|disulfide-linked heterodimers of CD94 and NKG2 subunits”. J Immunol. (1996) 157(11): 4741-4745.
[cited by applicant]
Liu et al., “IL-15 is highly expressed in inflammatory bowel disease and regulates local T cell-dependent cytokine production.” J Immunol. (2000) 164(7):3608-3615.
[cited by applicant]
Lonberg et al., “Human antibodies from transgenic mice”. Int Rev Immunol. (1995) 13: 65-93.
[cited by applicant]
Maiuri L. et al., “Interleukin 15 Mediates Epithelial Changes in Celiac Desease”, Gastroenter. (2000) 119:996-1006.
[cited by applicant]
McInnes et al., “Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis.” Nature Med. (1997) 3(2): 189-195.
[cited by applicant]
Mention J-J. et al., “Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease”, Gastroenter. (2003) 125(3):730-745.
[cited by applicant]
Meresse et al., “Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease.” Immunity (2004) 21(3):357-366.
[cited by applicant]
Meresse et al., “The cytokine interleukin 21: a new player in coeliac disease?.” Gut (2008) 57(7): 879-881.
[cited by applicant]
Mingari et al., “HLA class I-specific inhibitory receptors in human T lymphocytes: interleukin 15-induced expression of CD94/NK62A in superantigen- or alloantigen-activated CD8+ T cells”. Proc Natl Acad Sci. (1998) 95(3…
[cited by applicant]
Monteleone et al., “Interleukin-21 enhances T-helper cell type I signaling and interferon-γ production in Crohn's disease”, Gastroenterology (2005) 128(3): 687-694.
[cited by applicant]
Monteleone et al., “Characterization of IL-17A—Producing cells in celiac disease mucosa”, J Immunol. (2010) 184: 2211-2218.
[cited by applicant]
Nakou et al., “Interleukin-21 is increased in active systemic lupus erythematosus patients and contributes to the generation of plasma B cells.” Clin Exp Rheumatol. (2013) 31(2):172-179.
[cited by applicant]
Nohra et al., RGMA and IL21R show association with experimental inflammation and multiple sclerosis. Genes & Immunity, (2010) 11(4): 279-293.
[cited by applicant]
Nowak E.C. et al., “IL-9 as a mediator of Th17-driven inflammatory disease”, J Exp Med. (2009) 206:1653-1660.
[cited by applicant]
Oppenheimer-Marks et al., “Interleukin 15 is produced by endothelial cells and increases the transendothelial migration of T cells In vitro and in the SCID mouse-human rheumatoid arthritis model In vivo.” J Clin Invest …
[cited by applicant]
Padlan E.A., “A possible procedure for reducing the immunogenicity of antibody variabledomains while preserving their ligand-binding properties”. Mol Immunol. (1991) 28(4-5): 489-498.
[cited by applicant]
Pashenkov et al., “Levels of interleukin-15-expressing blood mononuclear cells are elevated in multiple sclerosis”, Scand J Immunol. (1999) 50(3):302-308.
[cited by applicant]
Petukhova et al., “Genome-wide association study in alopecia areata implicates both innate and adaptive immunity.” Nature (2010) 466(7302):113-117.
[cited by applicant]
Price-Troska et al., Inhibiting IL-2 Signaling And The Regulatory T-Cell Pathway Using Computationally Designed Peptides, Invest New Drugs, (2018) 37(1): 9-16.
[cited by applicant]
Recher et al., “IL-21 is the primary common γ chain-binding cytokine required for human B-cell differentiation in vivo”. Blood (2011) 118(26): 6824-6835.
[cited by applicant]
Richmond et al., “Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo”. Sci Transl Med. (2018) 10(450).
[cited by applicant]
Riechmann et al., “Reshaping human antibodies for therapy”. Nature (1988) 332: 323-327.
[cited by applicant]
Roguska et al., “Humanization of murine monoclonal antibodies through variable domain resurfacing”. Proc Natl Acad Sci. (1994) 91(3): 969-973.
[cited by applicant]
Rückert R. et al., “Interleukin-15 stimulates macrophages to activate CD4+ T cells: a role in the pathogenesis of rheumatoid arthritis?”, Immunology (2009) 126(1):63-73.
[cited by applicant]
Saha et al., “Prediction of continuous B-cell epitopes in an antigen using recurrent neural network”. Proteins (2006) 65: 40-48.
[cited by applicant]
Saikali et al., “Contribution of astrocyte-derived IL-15 to CD8 T cell effector functions in multiple sclerosis”, J Immunol. (2010) 185(10):5693-5703.
[cited by applicant]
Sarra M. et al., “IL-15 positively regulates IL-21 production in celiac disease mucosa”, Mucosal Immunol. (2013) 6(2):244-255.
[cited by applicant]
Sawalha et al., “Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus”, Ann Rheum Dis. (2008) 67(4):458-461.
[cited by applicant]
Schaller et al., “Interleukin-2 receptor expression and interleukin-2 production in bullous pemphigoid”. Arch Dermatol Res. (1990) 282(4): 223-226.
[cited by applicant]
Schneider et al., “B cell-derived IL-15 enhances CD8 T cell cytotoxicity and is increased in multiple sclerosis patients”, J Immunol. (2011) 187(8):4119-4128.
[cited by applicant]
Schumacher et al., “Severe combined immunodeficiencies of the common g-chain/JAK3 signaling pathway.” Isr. Med. Assoc. J. (2002) 4: 131-135.
[cited by applicant]
Shultz et al., “Humanized mice for immune system investigation: progress, promise and challenges”. Nat Rev Immunol. (2012) 12(11): 786-798.
[cited by applicant]
Sonntag et al., “Chronic graft-versus-host-disease in CD34(+)-humanized NSG mice is associated with human susceptibility HLA haplotypes for autoimmune diseases”. J Autoimmun. (2015) 62: 55-66.
[cited by applicant]
Studnicka et al., “Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues”. Protein Eng (1994) 7: 805-814.
[cited by applicant]
Suarez-Farinas et al., “Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing.” J Allergy Clin Immunol. (2015) 136(5): 1277-1287.
[cited by applicant]
Sushama et al., “Cytokine profile (IL-2, IL-6, IL-17, IL-22, and TNF-alpha) in vitiligo-New insight into pathogenesis of disease”. J Cosmet Dermatol. (2019) 18(1): 337-341.
[cited by applicant]
Tang et al., “Cytosolic PLA2 is required for CTL-mediated immunopathology of celiac disease via NKG2D and IL-15.” J Exp Med. (2009) 206(3): 707-719.
[cited by applicant]
Terrier et al., “Interleukin 21 Correlates with T Cell and B Cell Subset Alterations in Systemic Lupus Erythematosus”, J Rheumatol. (2012) 39(9):1819-1828.
[cited by applicant]
Tomimatsu et al., “Antigen-specific in vitro immunization: a source for human monoclonal antibodies”. Methods Mol Biol. (2014) 1060 (Chapter 15): 297-307.
[cited by applicant]
Tzartos et al., “IL-21 and IL-21 Receptor Expression in Lymphocytes and Neurons in Multiple Sclerosis Brain”, Am J Pathol. (2011) 178(2):794-802.
[cited by applicant]
Vainer et al., “Colonic expression and synthesis of interleukin 13 and interleukin 15 in inflammatory bowel disease”, Cytokine (2000) 12(10):1531-1536.
[cited by applicant]
Vaknin-Dembinsky et al., “Membrane bound IL-15 is increased on CD14 monocytes in early stages of MS”, J Neuroimmunol. (2008) 195(1-2):135-139.
[cited by applicant]
Van Heel et al., “A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21.” Nat Genet. (2007) 39(7): 827-829.
[cited by applicant]
Vaughan et al., “Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library”. Nature (1996) 14(3): 309-314.
[cited by applicant]
Villadsen et al., “Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model”. J Clin Invest. (2003) 112: 1571-1580.
[cited by applicant]
Waldmann, T.A., “The biology of IL-15: implications for cancer therapy and the treatment of autoimmune disorders.” J Investig Dermatol Symp Proc. (2013) 16(1):S28-S30.
[cited by applicant]
Walensky L.D et al., “Hydrocarbon-Stapled Peptides: Principles, Practice, and Progress”, Miniperspective; J Med Chem. (Aug. 2014) 57(15):6275-6288.
[cited by applicant]
Williams et al., “Humanising Antibodies by CDR Grafting.”, in: Antibody Engineering, eds R. Kontermann and S. Dübel (Springer—Berlin, Heidelberg); (2010) Chapter 21: 319-339.
[cited by applicant]
Witkowski A. et al., “Conversion of a beta-Ketoacyl Synthase to a Malonyl Decarboxylase by Replacement of the Active-Site Cysteine with Glutamine”, Biochem. (1999) 38:11643-11650.
[cited by applicant]
Xing et al., “Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.” Nat Med. (2014) 9:1043-1049.
[cited by applicant]
Xing et al., “Interleukin-21 induces migration and invasion of fibroblast-like synoviocytes from patients with rheumatoid arthritis”, Clin Exp Immunol. (May 2016) 184(2):147-158.
[cited by applicant]
Xing et al., “Interleukin-21 Induces Proliferation and Proinflammatory Cytokine Profile of Fibroblast-like Synoviocytes of Patients with Rheumatoid Arthritis”, Scand J Immunol. (Jan. 2016) 83(1):64-71.
[cited by applicant]
Yano et al., “Interleukin 15 induces the signals of epidermal proliferation through ERK and PI 3-kinase in a human epidermal keratinocyte cell line, HaCaT.” Biochem Biophys Res Comm. (2003) 301(4): 841-847.
[cited by applicant]
Yao et al., “SVMTriP: A Method to Predict Antigenic Epitopes Using Support Vector Machine to Integrate Tri-Peptide Similarity and Propensity”. PLoS One (2012) 7(9): e45152.
[cited by applicant]
Zanzi et al., “IL-15 interferes with suppressive activity of intestinal regulatory T cells expanded in Celiac disease.” Am J Gastroenter (2011) 106(7): 1308-1317.
[cited by applicant]
Zeng et al., “Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function.” J Exp Med. (2005) 201(1): 139-148.
[cited by applicant]
Office Action dated Jun. 6, 2020 in Australian Application No. 2019202527.
[cited by applicant]
Office Action dated Dec. 19, 2019 for Canadian Patent Application No. 2824515.
[cited by applicant]
Extended European Search Report dated Feb. 10, 2020 in European Application No. 19206731.2.
[cited by applicant]
Office Action dated Jun. 23, 2020 in Japanese Application No. 2017-090501.
[cited by applicant]
Office Action dated Sep. 29, 2020 in Japanese Application No. 2019-152602.
[cited by applicant]
Office Action dated May 27, 2020 in Australian Application No. 2020201174.
[cited by applicant]